It is therefore important to understand how the most recently developed breast and ovarian cancer PRS modify cancer risks for BRCA1/2 carriers, as this information will be necessary for implementation studies to evaluate how their application influences cancer risk management for women with pathogenic variants in these genes. This evidence concerns the gene BRCA1 and cancer.